Form 4: Arcadia Biosciences Director Acquires Stock Options

Lilian Shackelford Murray, a director of Arcadia Biosciences, acquired stock options exercisable for 10,909 shares of common stock on August 19, 2024.

Summary

• Lilian Shackelford Murray, a director at Arcadia Biosciences, acquired stock options on August 19, 2024.
• The options grant the right to buy 10,909 shares of Arcadia Biosciences common stock at an exercise price of $2.71 per share.
• The options vest fully on the earlier of August 19, 2025, or the date of the Issuer's next Annual Meeting of Stockholders, contingent upon continued service.
• Following the transaction, Murray directly owns 13,287 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring stock options suggests confidence, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, suggesting an expectation of Murray's continued involvement with Arcadia Biosciences.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency into insider activity and can be used by investors to gauge management's sentiment towards the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, director, RKDA, Arcadia Biosciences, Form 4, beneficial ownership